Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
심효섭, 정진행, 김루시아, 장선희, 김완섭, 이건국, 정순희, 장세진,
소속 상세정보
심효섭 ( Shim Hyo-Sup )
Yonsei University College of Medicine Department of Pathology
정진행 ( Chung Jin-Haeng )
Seoul National University Bundang Hospital Department of Pathology
김루시아 ( Kim Lucia )
Inha University College of Medicine Department of Pathology
장선희 ( Chang Sun-Hee )
Inje University Ilsan Paik Hospital Department of Pathology
김완섭 ( Kim Wan-Seop )
Konkuk University College of Medicine Department of Pathology
이건국 ( Lee Geon-Kook )
National Cancer Center Department of Pathology
정순희 ( Jung Soon-Hee )
Yonsei University Wonju College of Medicine Department of Pathology
장세진 ( Jang Se-Jin )
University of Ulsan College of Medicine Asan Medical Center Department of Pathology
KMID : 0357920130470020100
Abstract
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
키워드
Mutation; Receptor; epidermal growth factor; Guideline
원문 및 링크아웃 정보
등재저널 정보